ImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035 Yahoo Finance
Roche's ctDNA-guided approach in post-surgical bladder cancer pays off with Tecentriq nod Fierce Pharma
Kathryn H. Gessner, MD, PhD, on the most exciting current developments in bladder cancer Urology Times
AUA 2026: Debate: Systemic Therapy in MIBC – Follow the Protocol or Use Risk Adapted Therapy? UroToday
What's Going On With ImmunityBio Stock Monday? - ImmunityBio (NASDAQ:IBRX) Benzinga
Trial Questions Extended Antibiotics After Bladder Removal Medscape
Perioperative Imfinzi plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial AstraZeneca
New urine test may help tailor bladder cancer treatment Medical News Today
AUA 2026: Final Results of a Phase II Trial of BCG And Intravesical Gemcitabine for Patients With BCG-Exposed High-Grade Non-Muscle Invasive Bladder Cancer UroToday
Understanding treatment response in high-risk bladder cancer Medical Xpress
FDA Approves Atezolizumab for Muscle-Invasive Bladder Cancer Oncology News Central
Smoking and bladder cancer: What you need to know this Bladder Cancer Awareness Month Baylor College of Medicine Blog Network -
Indirect Comparison Favors Nogapendekin Alfa Inbakicept + BCG Over Nadofaragene in BCG-Unresponsive NMIBC Targeted Oncology
Roche's Tecentriq Wins FDA Nod for Label Expansion in Bladder Cancer Zacks Investment Research
ImmunityBio Shares Rise After Securing Five New U.S. Patents for Bladder Cancer Therapy (IBRX) Yahoo Finance
FDA Approves Atezolizumab for ctDNA-Positive Muscle-Invasive Bladder Cancer Oncology Nursing News
IMFINZI® (durvalumab) regimen reduced early disease recurrence among high-risk non-muscle-invasive bladder cancer patients in POTOMAC Phase III trial exploratory analyses AstraZeneca US
Valar Labs hits US first with breakthrough designation for AI bladder cancer test Medical Device Network
FDA Approves Adjuvant Atezolizumab for MRD+ Muscle-Invasive Bladder Cancer OncLive
Mouse bladder study: oral PV-10, two survivors with no gross bladder tumor Stock Titan
Shilpa Gupta: Energized by Momentum and Innovation Shaping Bladder Cancer Care after AUA 2026 Oncodaily
Detalimogene Therapy Tied to Responses in Heavily Pretreated, BCG-unresponsive NMIBC Oncology News Central
AstraZeneca scores with Imfinzi in another bladder cancer trial, rivaling Merck's Keytruda Fierce Pharma
Real-World Use of a Urinary Biomarker in a Large Integrated Health System - Christopher Filson UroToday
Major Complete Response Rate in Very High-Risk Bladder Cancer With Combo Treatment MedPage Today
Natera jumps after Signatera CDx wins FDA companion diagnostic approval in bladder cancer Quiver Quantitative
Stephen B. Williams: AUA26 Debate on the Cost of Treating Non–Muscle Invasive Bladder Cancer Oncodaily
FDA Approves Tecentriq for Bladder Cancer With Detected DNA After Surgery CUREtoday.com
Phase 1/2 trial evaluates recombinant BCG in BCG-naïve NMIBC Urology Times
Highlighting the Role of Real-World Studies in Bladder Cancer OncLive
FDA clears Roche's Tecentriq, paired with ctDNA test, for bladder cancer FirstWord Pharma
Preoperative Intravesical Mitomycin-C Before TURBT Cuts Recurrence Risk by 77% in NMIBC Over 5 Years OncLive
Retrospective Cohort Analysis of Blue-Light Cystoscopy Using a Claims Database - Mark Tyson UroToday
FDA Approves Genentech’s Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment BioSpace
Durvalumab Plus BCG Cut Early Recurrence of High-Risk Bladder Cancer MedPage Today
ImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035 Business Wire
Half of Patients With Post-BCG Bladder Cancer Achieve CR With Nonviral Gene Therapy MedPage Today
NTRA's Signatera CDx Wins FDA Nod in Muscle-Invasive Bladder Cancer The Globe and Mail
Signatera CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC) Business Wire
Bladder Cancer Advocacy Network Discusses Why Bladder Cancer Demands Attention Now with YourUpdateTV Yahoo Finance